Publication | Open Access

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Breast OncologyMedicinePathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentOncologyRadiation Oncology